Pipeline

Broadening Our Developmental Pipeline

Pipeline Chart, as of May 2017

Pipeline Overview

Pipeline Overview

BeyondSpring is currently conducting a global Phase 2/3 program of Plinabulin in preventing chemotherapy-induced neutropenia, and a pivotal Phase 3 trial evaluating Plinabulin for second-and third-line non-small cell lung cancer (NSCLC).

As BeyondSpring has further studied Plinabulin at the mechanistic and molecular levels, the Company has discovered additional applications, which has enhanced its view of the drug’s long-term potential and validated its initial belief that Plinabulin has significant potential benefit beyond its initial targeted indications.

Given Plinabulin’s potential as a tumor micro-environment-targeting agent, BeyondSpring intends to initiate clinical trials in additional cancer indications:

  • Immuno-oncology, with immune checkpoint inhibitors in NSCLC
  • CNS malignancies including metastatic brain tumors
  • KRAS positive mutant cancers

BeyondSpring plans to initiate a Plinabulin immuno-oncology program to assess the safety and efficacy of Plinabulin in combination with PD-1 checkpoint inhibitor(s) to treat patients with advanced NSCLC.

Earlier-stage immuno-oncology drug candidates in the Company’s pre-clinical pipeline include BPI-002, an oral small molecule activating T cells, BPI-003, a novel, oral small molecule IKK inhibitor, and BPI-004, a neo-antigen.

Pipeline Assets

BeyondSpring has obtained an exclusive license from University of Washington for a platform technology focused on the ubiquitin ligase protein to degrade a multitude of oncogenes and targets that had been previously undruggable using small molecule “molecular glue” compounds. Through this collaboration, the Company plans to use its combined resources to screen and optimize potential solutions and use oncology clinical expertise to quickly advance identified candidate into the clinic for testing. Dr. Lan Huang, co-founder of BeyondSpring and Dr. Ning Zheng, HHMI investigator from University of Washington, are the pioneers who solved the first structures of E3 ligase classes, which are key enzymes to target in this platform. Revlimid, a similar kind of “molecular glue,” is a marketed product that has generated more than $7 billion dollars in peak annual sales.